<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01855737</url>
  </required_header>
  <id_info>
    <org_study_id>2011-GZH1</org_study_id>
    <nct_id>NCT01855737</nct_id>
  </id_info>
  <brief_title>The Study of Warfarin Maintenance Dose in Chinese Patients</brief_title>
  <acronym>WADCH</acronym>
  <official_title>Clinical Study of the Relationship Between Pharmacogenomics and Warfarin Dose in Chinese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Title: Clinical study of the relationship between Pharmacogenomics and warfarin dose in
           Chinese patients

        2. Drug: Warfarin

        3. Design: To value the accuracy of warfarin Pharmacogenomics algorithm by the algorithm
           calculated dose and actual dose in the Chinese patients.

        4. Hypothesis:Pharmacogenomic algorithm guided dose can help to predict warfarin dose in
           Chinese patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  For the patients who need to use warfarin, detect the &quot;Vitamin K epoxide reductase
           complex subunit 1 (VKORC1),cytochrome p450 2C9 (CYP2C9), and cytochrome p450 4F2
           (CYP4F2) genotype.

        -  Record the demographic information: gender, age, height, and weight.

        -  Record drug combination, complications, and international normalized ratio (INR), liver
           function and kidney function or other biochemical test results.

        -  Put genotypes, demographic information and other clinical information into the algorithm
           to calculate warfarin dose for the patients, and compared with the actual dose.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The accuracy of the pharmacogenomics algorithm for warfarin maintenance dose</measure>
    <time_frame>one month after the initial dose of warfarin</time_frame>
    <description>The proportion of the patients whose predicted dose were within 20% of the actual maintenance dose.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Heart Valve Disease</condition>
  <condition>Pulmonary Artery Embolism</condition>
  <arm_group>
    <arm_group_label>Warfarin Using Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Prescribe warfarin to the patients who are needed.</description>
    <arm_group_label>Warfarin Using Group</arm_group_label>
    <other_name>Manufacturer: Orion Corporation</other_name>
    <other_name>Product Name: Warfarin</other_name>
    <other_name>3mg*100</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples with DNA frozen in -80℃
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese Han population who need to use Warfarin and older than 18 years old.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese patients

          -  Age &gt;18y

          -  target INR 1.5~3.0

          -  Patients signed informed consent

        Exclusion Criteria:

          -  Has hemorrhage disease, or tendency to significant bleeding

          -  Severe liver and kidney disfunction, serious infections, severe heart failure (NYHA
             heart function classification Ⅲ magnitude), severe pulmonary hypertension, abnormal
             thyroid function, respiratory failure, anemia, malignant tumor, blood disease

          -  patients with pregnancy or lactation;

          -  with cognitive impairment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yishi Li, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong Liu, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong Liu, MS</last_name>
    <phone>+86 10 88398547</phone>
    <email>winterliucn@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Li, MD</last_name>
    <phone>+86 10 88396298</phone>
    <email>sophialiyan1987@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yishi Li, MD, PhD</last_name>
      <phone>+86 10 88398395</phone>
      <email>lchyl_fuwai@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Yiling Huang, MS</last_name>
      <phone>+86 10 88398395</phone>
      <email>hyl0109@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yan Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ying Lou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2013</study_first_posted>
  <last_update_submitted>June 2, 2013</last_update_submitted>
  <last_update_submitted_qc>June 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Hong Liu</investigator_full_name>
    <investigator_title>Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health</investigator_title>
  </responsible_party>
  <keyword>gene guided</keyword>
  <keyword>warfarin dose</keyword>
  <keyword>Chinese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

